Effects of inhaled bronchodilators and corticosteroids on exercise induced arterial hypoxaemia in trained male athletes

A N H Hodges, B M Lynn, M S Koehle, D C McKenzie


table of contents

H istorically, 50% of highly trained male athletes and a greater number of female athletes develop exercise induced arterial hypoxaemia (EIAH) during maximal exercise. These athletes, unable to maintain arterial oxygen saturation (SaO₂) show decreases in indicators of endurance performance and a reduced maximal aerobic capacity. These observations have fuelled research over the last two decades to investigate the possible mechanisms, which include ventilation, ventilation perfusion inequality, and pulmonary intrapulmonary shunting of blood, relative alveolar hypoventilation, alteration in alveolar perfusion, and airway or vascular tone. These mechanisms have attracted a great deal of attention but the underlying causes of EIAH have yet to be completely understood. It has been documented that athletes unable to maintain SaO₂ show hindered physical performance in terms of decreased maximal aerobic capacity and physical working capacity.

In this study, the response to asthma inhaler medication was examined in normal subjects assumed to be non-asthmatic. Subjects with asthma have increased inflammation of the lung, and compromised ventilation secondary to bronchoconstriction is common. The standard of care for these patients is the administration of inhaled corticosteroids and bronchodilators. These drugs are effective in reversing airway obstruction and reducing lung inflammation, which allows asthmatics to perform sport and physical activity similar to normal, healthy people.

Strenuous exercise, in asthmatic and non-asthmatic athletes, initiates an acute inflammatory response with leucocytosis, neutrophil activation, and release of inflammatory mediators and acute phase proteins. Mediators of airway or vascular tone can also alter ventilation and/or perfusion distributions, and this observation is supported by increased histamine concentrations in athletes with EIAH, and improvement in impaired gas exchange with the administration of nedocromil sodium.

Anti-inflammatory drugs have been administered immediately before exercise, and the effects on EIAH observed. To our knowledge, a combination of bronchodilators and corticosteroid drugs, used daily to suppress lung inflammation and reverse bronchoconstriction, has not been used to attenuate EIAH in athletes who experience this condition. Fluticasone is a corticosteroid that inhibits production of inflammatory cells (mast cells, basophils, lymphocytes) and cytokines. Salbutamol is a selective short acting β₂ adrenergic agonist that acts as a bronchodilator. The purpose of this study therefore was to examine the effect of a seven day therapeutic administration of fluticasone and salbutamol on the SaO₂ of subjects with demonstrated EIAH.

METHODS

Subjects
Written informed consent was obtained from all subjects before participation. No subject was taking any drugs, and none presented symptoms of any infection during the study. The University of British Columbia Committee on Human Experimentation approved this study.

Experimental design
A randomised, double blinded, crossover design was used. Subjects reported to the laboratory on four separate occasions separated by at least 72 hours. On the first screening visit, anthropometric measures were recorded and an incremental maximal cycle to exhaustion test (maximum oxygen consumption (VO₂MAX) test) was performed. The second visit was also used for screening purposes and was identical with the first visit.

The third visit was a wash out period. The fourth visit was the study visit. The university research ethic committee approved the study. No subject was taking any drugs, and none presented symptoms of any infection during the study. The University of British Columbia Committee on Human Experimentation approved this study.

Abbreviations:
EIAH, exercise induced arterial hypoxaemia; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; SaO₂, arterial oxygen saturation; VO₂MAX, maximum oxygen consumption


See end of article for authors’ affiliations
Correspondence to: A N H Hodges, School of Human Kinetics, University of British Columbia, Vancouver, V6T 2G9, Canada; alastairhodges@hotmail.com
Accepted 23 May 2005
Subjects performed three trials, and the highest FEV1 was recorded. For inclusion in the study, an FEV1/forced vital capacity (FVC) greater than 0.8 was required. However, a third and fourth sessions, subjects completed a VO2MAX test after seven days of the drug (D) or placebo (P) condition in a randomised order. There was a minimum of seven days washout period between the placebo and drug conditions.

To ensure that all of the subjects had normal resting pulmonary function, flow volume loops and forced expiratory volume in one second (FEV1) were performed before each visit to the laboratory. Calibration was performed before each session. The purpose of the second identical VO2MAX test was to show reproducible EIAH. On the third and fourth sessions, subjects completed a VO2MAX test after seven days of the drug (D) or placebo (P) condition in a randomised order. There was a minimum of seven days washout period between the placebo and drug conditions.

The maximal exercise test
Subjects were requested not to perform any exhaustive exercise for 24 hours before each testing session. The graded exercise test was performed on an electronically braked cycle ergometer (Quinton Excalibur, Lode, Groningen, the Netherlands). Subjects started at 0 W and increased at a rate of 30 W/min and were encouraged to maintain pedal speed above 90 rev/min. The test stopped when they experienced volitional fatigue and could not maintain this speed above 90 rev/min. The test stopped when they experienced volitional fatigue and could not maintain this speed above 90 rev/min. The lowest SaO2 value was obtained during the last minute of the VO2MAX test. It is preferable to monitor EIAH through direct measurement of PO2 in arterial blood. However, we were limited in our ability to perform this measure on the population of subjects selected in this study. This should be noted as a limitation in the study methods that may lead to some inaccuracies in our assessment of EIAH in these subjects.

Drug administration
Twice daily, for seven days, subjects inhaled 400 µg salbutamol and 500 µg fluticasone from two separate inhalers or an identical placebo that had no active medication. The final administration of the two inhalers took place in the laboratory 15 minutes before the beginning of the exercise test. In the placebo condition, two inhalers were also used to maintain the integrity of the blinding. The order of administration of the two drugs was not controlled. An AeroChamber (Boehringer Ingelheim, Burlington, Ontario, Canada) spacer was used to maximise inhalation of the drugs. Detailed instruction and practice with the inhalers were given to each subject. The inhalers were randomly coded, enabling double blinding of the administration order.

Data analysis
Multiple analysis of variance was used to assess SaO2, VO2MAX, peak power, ventilation (Ve), and heart rate data for each treatment condition. A repeated measures analysis of variance was used to examine SaO2 over time during the exercise test in each condition. For all analyses, α was set at 0.05.

RESULTS
Nine healthy male subjects participated in this study (mean (SD) age 26.3 (6.7) years; VO2MAX 62.3 (6.3) ml/kg/min). Normal spirometry data were obtained on all nine subjects. Table 1 shows mean maximal exercise data for the nine subjects, and table 2 shows FVC, FEV1, and forced expiratory flow from 25% to 75% for the individual subjects. No significant differences were found between the drug and placebo conditions for minimum SaO2 (p = 0.93), VO2MAX (p = 0.91), peak power (p = 0.90), peak Ve (p = 0.82), or maximal heart rate (p = 0.76) (table 1). There was a significant decrease in SaO2 from rest at 50%, 75%, and 100% VO2MAX for each treatment (p<0.05), but there were no

---

Table 1  Maximal exercise data

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>SaO2 (%)</td>
<td>93.0 (1.1)</td>
<td>93.6 (1.4)</td>
</tr>
<tr>
<td>VO2MAX [ml/kg/min]</td>
<td>61.9 (6.3)</td>
<td>61.5 (7.2)</td>
</tr>
<tr>
<td>Power (W)</td>
<td>449.4 (43.9)</td>
<td>444.4 (48.3)</td>
</tr>
<tr>
<td>Ve (litres/min)</td>
<td>149.2 (15.5)</td>
<td>147.8 (19.1)</td>
</tr>
<tr>
<td>HRmax (beats/min)</td>
<td>180.8 (5.5)</td>
<td>182.3 (10.0)</td>
</tr>
</tbody>
</table>

Values are means (SD) (n = 9).

SaO2, arterial oxygen saturation; VO2MAX, maximum oxygen consumption; HRmax, maximum heart rate.

Table 2  Individual spirometry data

<table>
<thead>
<tr>
<th>Subject</th>
<th>FVC (litres)</th>
<th>FEV1/FVC (%)</th>
<th>FEF25–75 (litres/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5.3</td>
<td>84.3</td>
<td>4.8</td>
</tr>
<tr>
<td>2</td>
<td>7.3</td>
<td>80.9</td>
<td>4.5</td>
</tr>
<tr>
<td>3</td>
<td>5.5</td>
<td>82.3</td>
<td>4.2</td>
</tr>
<tr>
<td>4</td>
<td>5.9</td>
<td>80.7</td>
<td>5.7</td>
</tr>
<tr>
<td>5</td>
<td>5.6</td>
<td>81.0</td>
<td>4.3</td>
</tr>
<tr>
<td>6</td>
<td>5.4</td>
<td>86.2</td>
<td>4.8</td>
</tr>
<tr>
<td>7</td>
<td>6.4</td>
<td>82.4</td>
<td>5.9</td>
</tr>
<tr>
<td>8</td>
<td>4.4</td>
<td>80.2</td>
<td>4.7</td>
</tr>
<tr>
<td>9</td>
<td>5.2</td>
<td>81.4</td>
<td>5.0</td>
</tr>
<tr>
<td>Mean</td>
<td>5.8</td>
<td>82.2</td>
<td>4.9</td>
</tr>
<tr>
<td>SD</td>
<td>0.8</td>
<td>2.0</td>
<td>0.6</td>
</tr>
</tbody>
</table>

FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF25–75, forced expiratory flow from 25% to 75%.

---

Figure 1  Arterial oxygen saturation (SaO2) during incremental exercise. VO2MAX, maximum oxygen consumption. *Drug significantly lower than rest (p<0.05). †Placebo significantly lower than rest (p<0.05).
Exercise induced arterial hypoxaemia and asthma inhalers

Figure 2 Drug condition: individual arterial oxygen saturation (SaO₂). VO₂MAX, maximum oxygen consumption.

significant differences in SaO₂ between treatments at any workload (fig 1). Figures 2 and 3 show the individual SaO₂ exercise data for the drug and placebo conditions respectively. All nine subjects showed a minimum fall of 4% in SaO₂ in the first two VO₂MAX tests.

DISCUSSION

Our results indicate that a seven day treatment with an inhaled bronchodilator and corticosteroid did not alter SaO₂ during incremental cycling exercise to exhaustion in non-asthmatic trained male athletes with EIAH.

Airway inflammation occurs during exercise induced asthma and may limit exercise in asthmatics. We hypothesised that similar response in healthy subjects may contribute to EIAH. Previously, drugs normally used in the control of the asthma inflammatory response in asthmatics have been shown to make some reduction in arterial haemoglobin desaturation when the subject were exercised. Inhaled nedocromil sodium, a histamine release inhibitor, has been shown to improve pulmonary gas exchange in several classes of athletes including male master athletes (63.2 (1.9) years) and aerobically trained men and women when administered in conjunction with fexofenadine hydrochloride (a peripheral H1 receptor antagonist) and zileuton (a leukotriene inhibitor). A recent study has examined the effects of a single dose of a long or short acting β2 agonist (formoterol and salbutamol respectively) on trained non-asthmatic subjects during cycle ergometer exercise to exhaustion. No significant differences were found for any maximal exercise variables (workload, VO₂, VE, and SaO₂) between the two drugs or the placebo condition. It appears then that, if an inflammatory response is the cause of EIAH in these subjects, either specific drugs but not others mediate this response, or clearly there are other mechanisms involved in the decrease in SaO₂ during exercise.

It was our belief that a longer term control of lung inflammation may be useful in examination of the hypoxaemic response in these subjects. Previous studies involving the administration of drugs in subjects with EIAH have used a single dose immediately before exercise. This study was unique with the use of a corticosteroid inhaler for seven days. Any chronic lung inflammation would have been controlled through the effects of the prolonged use of a bronchodilator and corticosteroid.

It is worth noting that paradoxical bronchoconstriction and/or bronchospasm have been observed after administration of β2 agonist drugs. It may be prudent in the study of the effect of such drugs on exercise to include spirometry measures before and after each administration of the drug. Regular spirometry measures were a limitation in this study because of the nature of the self administration of the drugs at home for seven days. Nevertheless, none of our subjects reported any symptoms of bronchoconstriction or complained of any change in breathing ability after administration of the β2 agonist.

A further limitation of this study was our decision to use the determination of VO₂MAX as the exercise challenge. Although the advantage of this type of exercise is that EIAH is readily reproducible, it may have been prudent to have subjects maintain a high intensity of exercise for an extended period of time. In this type of study examining the role of airway inflammation on EIAH, it is possible that, during a prolonged exercise bout, subjects would show greater airway irritation and inflammation.

We found no difference in any exercise data after a seven day administration of inhaled bronchodilators and corticosteroids, and therefore we conclude that inhaled asthma drugs of this nature have no effect on EIAH.

What is already known on this topic

It has been shown that an inhaled bronchodilator has no effect on exercise induced arterial hypoxaemia.

What this study adds

This study shows that a combination of inhaled corticosteroids and bronchodilators does not have any effect on exercise induced arterial hypoxaemia, strengthening the notion that this condition is not the result of lung airway inflammation.

ACKNOWLEDGEMENTS

We thank Diana Jespersen for her technical assistance with this study.

www.bjsportmed.com
REFERENCES


ELECTRONIC PAGES

Online case reports

Lateral plantar nerve injury following steroid injection for plantar fasciitis

M D Snow, J Reading, R Dalal

A 41 year old man presented with pain and numbness affecting the lateral aspect of his foot after a steroid injection for plantar fasciitis. Examination confirmed numbness and motor impairment of the lateral plantar nerve. The findings were confirmed by electromyographic studies. The anatomy of the lateral plantar nerve and correct technique for injection to treat plantar fasciitis are discussed.


Popliteus tendon tenosynovitis

S M Blake, N J Treble

This case report highlights an unusual cause of anterolateral knee pain. The popliteus muscle arises from three origins—that is, the lateral femoral condyle, the fibula head, and the lateral meniscus—and inserts into the proximal tibia above the soleal line. It may be subjected to a number of pathologies including tenosynovitis, acute calcific tendonitis, rupture, and even avulsion. In this case, the diagnosis of popliteus tendon tenosynovitis was not made from magnetic resonance imaging findings, but was confirmed and successfully treated during arthroscopic examination.

Effects of inhaled bronchodilators and corticosteroids on exercise induced arterial hypoxaemia in trained male athletes
A N H Hodges, B M Lynn, M S Koehle and D C McKenzie

doi: 10.1136/bjsm.2005.017806

Updated information and services can be found at:
http://bjsm.bmj.com/content/39/12/917

These include:

References
This article cites 11 articles, 4 of which you can access for free at:
http://bjsm.bmj.com/content/39/12/917#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Asthma (33)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/